Pressure onMerck/Schering-PloughPharmaceuticals Vytorin (ezetimibe plus simvastatin) is set to continue after the SEAS study showed that the combination hypolipaemic product failed to reach its primary endpoint in a new indication of aortic stenosis, and was associated with an increased risk of developing cancer.
Independent experts have stressed that the higher cancer rate appears due to the play of chance, and point out that...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?